v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Operating activities:    
Net (loss) income $ (13,600) $ 254
Adjustments to reconcile net (loss) income to net cash used in operating activities:    
Stock-based compensation expense 6,154 5,308
Depreciation and amortization 981 1,162
Amortization of debt discount and debt issuance costs 446 417
Accretion of discount on short-term investments (294) (520)
Retirement and impairment of property and equipment 7 0
Loss on disposal of property and equipment 0 95
Change in operating assets and liabilities:    
Accounts receivable 16 (1,050)
Inventory (852) (19,805)
Prepaid expenses and other assets 2,322 698
Accounts payable 2,545 328
Accrued clinical and manufacturing liabilities (1,019) (8,083)
Accrued payroll and employee related liabilities (2,638) (3,083)
Other accrued expenses 2,179 4,541
Net cash used in operating activities (3,753) (19,738)
Investing activities:    
Purchases of short-term investments (27,856) (32,087)
Maturities and sales of short-term investments 24,181 41,958
Purchases of property and equipment (529) (317)
Proceeds from sale of property and equipment 0 53
Net cash (used in) provided by investing activities (4,204) 9,607
Financing activities:    
(Payments) receipts for stock issued under the equity incentive plan (194) 258
Proceeds from purchases under the employee stock purchase plan 225 587
Net cash provided by financing activities 31 845
Net decrease in cash and cash equivalents (7,926) (9,286)
Cash and cash equivalents at beginning of period 28,647 25,802
Cash and cash equivalents at end of period 20,721 16,516
Supplemental disclosure of cash flow information:    
Interest paid 5,320 2,412
Right-of-use assets obtained in exchange for new operating lease liabilities $ 5,695 $ 0